These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 16155076)
1. Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome. Cataldo NA; Abbasi F; McLaughlin TL; Basina M; Fechner PY; Giudice LC; Reaven GM Hum Reprod; 2006 Jan; 21(1):109-20. PubMed ID: 16155076 [TBL] [Abstract][Full Text] [Related]
2. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Baillargeon JP; Jakubowicz DJ; Iuorno MJ; Jakubowicz S; Nestler JE Fertil Steril; 2004 Oct; 82(4):893-902. PubMed ID: 15482765 [TBL] [Abstract][Full Text] [Related]
3. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations. Koo YA; Shin SY; Yoon BK; Choi D Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414 [TBL] [Abstract][Full Text] [Related]
4. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Kilicdag EB; Bagis T; Zeyneloglu HB; Tarim E; Aslan E; Haydardedeoglu B; Erkanli S Hum Reprod; 2005 Apr; 20(4):894-9. PubMed ID: 15618250 [TBL] [Abstract][Full Text] [Related]
5. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Yilmaz M; Bukan N; Ayvaz G; Karakoç A; Törüner F; Cakir N; Arslan M Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091 [TBL] [Abstract][Full Text] [Related]
6. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome. Mitkov M; Pehlivanov B; Terzieva D Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):93-8. PubMed ID: 16360262 [TBL] [Abstract][Full Text] [Related]
7. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome. Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572 [TBL] [Abstract][Full Text] [Related]
8. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Yilmaz M; Karakoç A; Törüner FB; Cakir N; Tiras B; Ayvaz G; Arslan M Gynecol Endocrinol; 2005 Sep; 21(3):154-60. PubMed ID: 16335907 [TBL] [Abstract][Full Text] [Related]
9. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Belli SH; Graffigna MN; Oneto A; Otero P; Schurman L; Levalle OA Fertil Steril; 2004 Mar; 81(3):624-9. PubMed ID: 15037412 [TBL] [Abstract][Full Text] [Related]
10. Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome. Liao L; Tian YJ; Zhao JJ; Xin Y; Xing HY; Dong JJ Chin Med J (Engl); 2011 Mar; 124(5):714-8. PubMed ID: 21518564 [TBL] [Abstract][Full Text] [Related]
11. Two weeks of metformin improves clomiphene citrate-induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Khorram O; Helliwell JP; Katz S; Bonpane CM; Jaramillo L Fertil Steril; 2006 May; 85(5):1448-51. PubMed ID: 16579997 [TBL] [Abstract][Full Text] [Related]
12. [Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome]. Ye BL; Yang HY; Zhao JZ; Lin JJ; Lin WQ Zhonghua Fu Chan Ke Za Zhi; 2003 Dec; 38(12):745-8. PubMed ID: 14728846 [TBL] [Abstract][Full Text] [Related]
13. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome. Fenkci SM; Fenkci V; Oztekin O; Rota S; Karagenc N Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560 [TBL] [Abstract][Full Text] [Related]
14. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. Sepilian V; Nagamani M J Clin Endocrinol Metab; 2005 Jan; 90(1):60-5. PubMed ID: 15483106 [TBL] [Abstract][Full Text] [Related]
15. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364 [TBL] [Abstract][Full Text] [Related]
16. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Sahin Y; Unluhizarci K; Yilmazsoy A; Yikilmaz A; Aygen E; Kelestimur F Clin Endocrinol (Oxf); 2007 Dec; 67(6):904-8. PubMed ID: 17666089 [TBL] [Abstract][Full Text] [Related]
17. [Effect of rosiglitazone on insulin resistance and hyperandrogenism in polycystic ovary syndrome]. Zheng Z; Li M; Lin Y; Ma Y Zhonghua Fu Chan Ke Za Zhi; 2002 May; 37(5):271-3. PubMed ID: 12133398 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome. Sönmez AS; Yasar L; Savan K; Koç S; Ozcan J; Toklar A; Yazicioğu F; Akgün A; Sut N Hum Reprod; 2005 Jan; 20(1):175-9. PubMed ID: 15513975 [TBL] [Abstract][Full Text] [Related]
19. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Legro RS; Zaino RJ; Demers LM; Kunselman AR; Gnatuk CL; Williams NI; Dodson WC Am J Obstet Gynecol; 2007 Apr; 196(4):402.e1-10; discussion 402.e10-1. PubMed ID: 17403436 [TBL] [Abstract][Full Text] [Related]
20. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. Lemay A; Dodin S; Turcot L; Déchêne F; Forest JC Hum Reprod; 2006 Jan; 21(1):121-8. PubMed ID: 16199428 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]